AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 272 min read$GLSI

Patel Snehal purchased $47K of GLSI

Patel Snehal (CEO and CFO) purchased 3,600 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.06 ($12.88–$13.14) across 2 trades over 2026-07-23 to 2026-07-24.

Original reporting
SEC EDGAR · Patel Snehal
Published Jul 27, 2026, 10:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 10:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GLSI
Bullish
medium confidence
Mentioned
$GLSI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLSIBullishLow
01

Why it matters

The disclosure provides a fresh datapoint on insider behavior (open-market purchase) but does not include new company performance, guidance, or regulatory/clinical milestones.

02

Market read

Traders may treat the buy as a small sentiment input, but it is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, but it still does not provide intent, motivation, or whether the insider has ongoing trading patterns.

Relevance 4/10Novelty 5/10Timing: new Form 4 filed 2026-07-27, covering buys on 2026-07-23 to 2026-07-24

Background

This is an SEC Form 4 insider transaction for Greenwich LifeSciences, Inc., reported by CEO and CFO Patel Snehal.

Company-level read

Ticker impact

$GLSIBullishMedium confidence
Context

CEO and CFO Patel Snehal bought 3,600 shares of Greenwich LifeSciences at about $13.06 via open-market trades, disclosed on Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and specific (shares, price range, dates), but the transaction size ($47k) is relatively small versus typical market-moving thresholds and provides no new operating or financial information.

Market effects

Sector

No sector-level implications; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine (tax planning, diversification, or pre-planned behavior) and do not necessarily reflect a change in fundamentals.

Key entities

  • issuer
    Greenwich LifeSciences, Inc.

    Subject of the Form 4 insider transaction; ticker GLSI.

  • insider
    Patel Snehal

    CEO and CFO who reported the open-market purchase.

Read at source← All news

Related articles

JUL 20
$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.

rttnews.com5 min
JUL 9
$GLSIMedAI 8/10

Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com

Greenwich LifeSciences (NASDAQ:GLSI) shares rose 7.7% after the European Medicines Agency approved commercially manufactured GP2 for its FLAMINGO-01 Phase III trial of GLSI-100 to prevent breast cancer recurrence. The approval lets US and Europe sites use the same GP2 lot. The company said sites increased to about 170-180 and shipments to European pharmacies are underway.

investing.com4 min
JUL 9
$GLSIMedAI 8/10

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences (Nasdaq: GLSI) said the EMA has completed review and will allow use of commercially manufactured GP2 in its FLAMINGO-01 Phase III trial of GLSI-100 in Europe. The same GP2 lot was approved for US use in early 2026 and is being used at about 170-180 sites. The company reported preliminary 70-80% recurrence reduction in a non-HLA-A*02 arm after the primary immunization series.

manilatimes.net4 min
JUL 9
$GLSIMedAI 8/10

Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences (Nasdaq: GLSI) said the EMA has completed review and will allow use of the same commercially manufactured GP2 lot in its FLAMINGO-01 Phase III trial in Europe. The FDA approved the first commercial GP2 vials for US use in early 2026. The company also reported preliminary non-HLA-A*02 recurrence-rate reductions of about 70-80% after the primary immunization series.

finanznachrichten.de4 min